- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2021–2026 · research · R01
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · cooperative agreement · UM1
Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R21
Exploring alternate targets for inhibition of virus infection by PPI disruption
Michael A Calderwood · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · fellowship · F32
Elucidating the Role of Epigenetic Plasticity in anti-GD2 Immunotherapy Response
Nathaniel Mabe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2022 · career development · K99
Understanding Ancestral Contribution to Lung Adenocarcinoma
Jian Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · fellowship · F32
Lipid metabolism as a therapeutic vulnerability in BET inhibitor-resistant medulloblastoma
Leslie Lupien · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K99
Functional Characterization of HER Family Variant Biology and Resistance in Cancer
Tikvah K Hayes · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · grant · KCRP
Pre-IND Studies of First-Generation Dual-Targeted, Fine-Tuned, Immune-Restoring (DFIR) CAR-T Cell Therapy to Achieve Cures of Clear Cell Renal Cell Carcinoma (ccRCC)
Wayne Marasco · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · cooperative agreement · UM1
Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R21
Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Can a subset of patients with HER2+ metastatic breast cancer be cured?
Heather Anne Parsons · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
Sahand Hormoz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial
Ting Bao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
Tao Zou · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2022 · research · R56
Defining the landscape and mechanisms of protein redox regulation during aging
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K99
Functional Characterization of HER Family Variant Biology and Resistance in Cancer
Tikvah K Hayes · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · grant · DP2
Discovery of cGAS-like signaling enzymes in innate immunity and disease
Philip J Kranzusch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · grant · KCRP
Further Optimizing 2nd Generation Dual-targeted Fine-tuned Immune-Restoring (DFIR) CAR T Cells to Achieve Cures of Advanced ccRCC
Wayne Marasco · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · research · R37
Targeting vulnerabilities of PPM1D-mutant gliomas
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Statistical methods for cancer mutational signatures
Giovanni Luigi Parmigiani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
Thanh Uyen Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021 · research · PCF Challenge Award
Leveraging Epigenomics to Target Acquired Vulnerabilities in Treatment Resistant Prostate Cancer
Matthew Freedman · Dana-Farber Cancer Institute · funded by Prostate Cancer Foundation
2021 · research
Improving outcomes for breast cancer patients in Rwanda by reducing stigma around the disease
Temidayo Fadelu · Dana-Farber Cancer Institute · funded by Breast Cancer Research Foundation
2021 · fellowship · AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship
Probing the dysregulation of SWI/SNF and PRC1/2 interplay in tumorigenesis
Siddhant U. Jain · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2021 · career development · Young Investigator Award
A Phase 2 Trial of Pembrolizumab and Lenvatinib in Recurrent or Persistent Clear Cell Carcinoma of the Ovary
Elizabeth Lee · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Young Investigator Award
A Phase 2 trial of palbociclib in combination with axitinib and avelumab in metastatic clear cell renal cell carcinoma.
Praful Ravi · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · fellowship · AACR-Bristol Myers Squibb Immuno-oncology Research Fellowship
Dissecting CTLA-4 and PD-1 cooperation in tumor immunity and adverse events
Kelly P. Burke · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2021 · career development · Young Investigator Award
Investigating the molecular mechanisms of immune escape in pancreatic adenocarcinoma to guide rational combination immunotherapy strategies
William Freed-Pastor · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Young Investigator Award
Detection of DNA damage repair (DDR) deficiency and neuroendocrine differentiation from circulating prostate cancer methylomes
Sylvan Baca · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Career Development Award
Improving adherence to adjuvant endocrine therapy among patients with breast cancer in Rwanda: a randomized intervention of symptom self-monitoring and motivational mobile text message reminders.
Temidayo Fadelu · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Young Investigator Award
Identifying Metabolic Drivers Controlling Cell State Transitions in Glioblastoma
Diana Shi · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Young Investigator Award
Phase 1 Study of Cabozantinib in Combination with Topotecan- Cyclophosphamide for Patients with Relapsed Ewing Sarcoma or Osteosarcoma
Kevin Campbell · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Young Investigator Award
Decoupling CTLA-4 and PD-1 pathway blockade in immune-related adverse events
Kelly Burke · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · career development · Young Investigator Award
Dissecting the contribution of germline genetics to pediatric sarcoma pathogenesis
Riaz Gillani · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2021 · fellowship · AACR-Bayer CORE Training Fellowshiips
AACR-Bayer CORE Training Fellowshiips 2021: Praful Ravi
Praful Ravi · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2021–2026 · cooperative agreement · UM1
Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2027 · research · R01
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
Thanh Uyen Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
